family with sequence similarity 216 member AGenealiases: C12orf24 · HSU79274
Q-omics provides the consensus-scored FAM216A profile across patient tissues and cancer cell-line models. FAM216A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FAM216A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM216A RNA expression shows 19,946 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where FAM216A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM216A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM216A survival associations across molecular data types. FAM216A RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM216A RNA expression–survival associations across cancer types. High FAM216A expression shows unfavorable associations in MESO, KIRP, LIHC, UVM, KICH and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FAM216A RNA expression.
This table summarizes FAM216A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM216A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM216A shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, LIHC, KIRP and HNSC. The KIRC box plot shows higher FAM216A RNA expression in tumor versus normal tissue (log2 FC = +0.922, t-test p < 0.001).
This table shows molecular features associated with FAM216A in patient tissues and cancer cell lines. In patient samples, FAM216A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM216A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and OVARY.
